Docetaxel and Temozolomide in Treating Patients With Metastatic Cancer

Phase 1 Completed 25 enrolled The Cleveland Clinic National Cancer Institute (NCI) · collab

NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy, such as docetaxel and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of docetaxel and temozolomide in treating patients with metastatic cancer.

Timeline

Start: 2002-06
Primary completion: 2008-07
Completion: 2008-07

Publications

Results Tamaskar I, Mekhail T, Dreicer R, Olencki T, Roman S, Elson P, Bukowski RM. Phase I trial of weekly docetaxel and daily temozolomide in patients with metastatic disease. Invest New Drugs. 2008 Dec;26(6):553-9. doi: 10.1007/s10637-008-9153-0. Epub 2008 Jul 15.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Docetaxel	Small molecule	25 mg/m2	Intravenous
Subject	Docetaxel	Small molecule	30 mg/m2	Intravenous
Subject	Docetaxel	Small molecule	35 mg/m2	Intravenous
Subject	Temozolomide	Small molecule	75 mg/m2	Oral
Subject	Temozolomide	Small molecule	90 mg/m2	Oral
Subject	Temozolomide	Small molecule	100 mg/m2	Oral

Docetaxel and Temozolomide in Treating Patients With Metastatic Cancer

Summary

Timeline

Publications

Drugs

Indications